Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Net Margin (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Net Margin readings, the most recent being 64.13% for Q4 2025.

  • On a quarterly basis, Net Margin rose 6730.0% to 64.13% in Q4 2025 year-over-year; TTM through Dec 2025 was 106.64%, a 5384.0% increase, with the full-year FY2025 number at 125.19%, up 4925.0% from a year prior.
  • Net Margin hit 64.13% in Q4 2025 for Enanta Pharmaceuticals, up from 122.9% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 64.13% in Q4 2025 to a low of 347.41% in Q3 2021.
  • Median Net Margin over the past 5 years was 149.3% (2023), compared with a mean of 159.23%.
  • Biggest five-year swings in Net Margin: tumbled -22325bps in 2021 and later surged 21560bps in 2022.
  • Enanta Pharmaceuticals' Net Margin stood at 108.92% in 2021, then dropped by -13bps to 122.9% in 2022, then tumbled by -51bps to 185.56% in 2023, then grew by 29bps to 131.43% in 2024, then soared by 51bps to 64.13% in 2025.
  • The last three reported values for Net Margin were 64.13% (Q4 2025), 122.9% (Q3 2025), and 99.68% (Q2 2025) per Business Quant data.